SpringWorks Therapeutics (SWTX) to Release Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect SpringWorks Therapeutics to post earnings of ($0.79) per share and revenue of $66.93 million for the quarter.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The company had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. On average, analysts expect SpringWorks Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

SpringWorks Therapeutics Stock Performance

SpringWorks Therapeutics stock opened at $41.27 on Thursday. The company has a 50 day moving average price of $46.68 and a 200 day moving average price of $40.33. SpringWorks Therapeutics has a 52 week low of $28.21 and a 52 week high of $62.00. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -11.86 and a beta of 0.79.

Insider Transactions at SpringWorks Therapeutics

In other news, insider Bhavesh Ashar sold 1,016 shares of SpringWorks Therapeutics stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the transaction, the insider now directly owns 62,053 shares in the company, valued at approximately $3,797,023.07. The trade was a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Daniel Lynch sold 175,000 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $54.46, for a total value of $9,530,500.00. Following the sale, the director now owns 130,944 shares of the company’s stock, valued at approximately $7,131,210.24. The trade was a 57.20 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 440,766 shares of company stock worth $24,402,956. 7.83% of the stock is owned by insiders.

Wall Street Analyst Weigh In

SWTX has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Evercore ISI raised their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Finally, Guggenheim decreased their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $73.20.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.